Top JPMorgan banker sees steady supply of Chinese health care IPOs, even amid valuation concerns

• Chinese companies and investors raised US$18.3 billion from 77 new and secondary listings globally last year, according to Refinitiv
• It is debatable whether record-high valuations can hold as investors chase a scarce supply of targets, says Fang Min of Warburg Pincus